Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

13.42
+1.9216.70%
Pre-market: 13.830.4100+3.06%06:34 EDT
Volume:1.60M
Turnover:20.92M
Market Cap:504.88M
PE:-7.80
High:13.55
Open:11.59
Low:11.59
Close:11.50
52wk High:17.79
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:2.68
T/O Rate:5.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.11
PE(LYR):-6.18

Loading ...

RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 31

Contineum Therapeutics Inc Expected to Post a Loss of 42 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Benzinga Earnings
·
Jul 31

Contineum Therapeutics Inc Q2 Net Loss Per Share $0.40

THOMSON REUTERS
·
Jul 31

Contineum Therapeutics - Implements Workforce Reduction Including Chief Scientific Officer Daniel Lorrain

THOMSON REUTERS
·
Jul 31

Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth

Simply Wall St.
·
Jul 17

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership

TIPRANKS
·
Jul 14

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 16,640 in Common Shares

Reuters
·
Jul 11

Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Shares for $40,000

Reuters
·
Jul 09

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 556,791 Common Shares

Reuters
·
Jul 03

Contineum Therapeutics CEO Carmine Stengone Sells 10,000 Common Shares for $160,080

Reuters
·
Jul 02

Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry

TIPRANKS
·
Jul 01

Contineum Launches Global Phase 2 Trial of Pipe-791 in Idiopathic Pulmonary Fibrosis Patients

Reuters
·
Jul 01

Contineum Stockholders Hold 2026 Virtual Annual Meeting

TIPRANKS
·
Jun 27

Contineum Therapeutics Shareholders Elect Class II Directors at Annual Meeting

Reuters
·
Jun 27

Contineum Therapeutics CSO Daniel S. Lorrain disposes of 4,170 common shares for $54,866.19

Reuters
·
Jun 02

Contineum Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 02

Contineum Therapeutics grants 51,000-share inducement stock option to new employee

Reuters
·
May 16

Contineum Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 15

Contineum price target raised to $16 from $14 at Morgan Stanley

TIPRANKS
·
May 15